News & Opinion
Top 10 Innovations
Cell & Molecular Biology
Disease & Medicine
Ecology & Environment
Genetics & Genomics
Pharma & Biotech
Image of the Day
CAR T cells
CAR T cells
Gilead to Pay Nearly $12B for CAR T-Cell Company
Jef Akst | Aug 28, 2017
The massive sum will buy out Kite Pharma, whose cancer therapy is expected to be among the first of its type approved by the FDA.
The Ever-Expanding T-Cell World: A Primer
Ashley P. Taylor | Aug 7, 2017
Researchers continue to identify new T-cell subtypes—and devise ways to use them to fight cancer.
attempts to catalog them all.
FDA Votes Yes on CAR T-Cell Therapy
Aggie Mika | Jul 13, 2017
A Food and Drug Administration advisory panel unanimously calls for agency approval of the cell therapy for the treatment of resistant leukemia.
CAR T-Cell Trials Boast Promising Results
Diana Kwon | Jun 5, 2017
The results of two small clinical trials show that the immunotherapy is effective for multiple myeloma patients, at least in the near term.
Making CAR T-Cell Therapy Safer
Catherine Offord | Apr 1, 2017
Following a spate of patient deaths in clinical trials testing modified T cells for the treatment of cancer, researchers work to reduce the treatment’s toxicity without sacrificing efficacy.
Hitting It Out of the Park
Mary Beth Aberlin | Apr 1, 2017
Cancer can be as evasive and slippery as a spitball, but new immunotherapies are starting to connect.
Kite’s CAR T-Cell Therapy Success
Jef Akst | Mar 1, 2017
More than one-third of lymphoma patients in a Phase 2 trial were clear of disease at six months, and no new safety concerns arose since the company’s three-month follow up.
Opinion: Balancing Risks and Rewards of CAR T-Cell Therapy
David Harris | Dec 15, 2016
New approaches to treating cancer have shown great promise, but they also come with serious risks that give us cause for concern.
TS Picks: June 6, 2016
Jef Akst | Jun 6, 2016
American Society of Clinical Oncology meeting edition